𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Fludarabine in the treatment of refractory lymphocytic leukemia (CLL) and low grade lymphoma (LGL)

✍ Scribed by Gillis, S.; Dann, E.J.; Rachmilewitz, E.A.; Polliack, A.

Book ID
123320919
Publisher
Elsevier Science
Year
1993
Tongue
English
Weight
130 KB
Volume
29
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Fludarabine and cytosine arabinoside in
Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia
✍ Samer Suki; Hagop Kantarjian; Varsha Gandhi; Elihu Estey; Susan O'Brien; Milosla πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 571 KB

## Background: The objectives of the study were to evaluate the antileukemic efficacy and toxicity profiles of the combination of fludarabine and intermediate-dose cytosine arabinoside (ara-c) in refractory or relapsed adult acute lymphocytic leukemia (all). patients and methods. thirty adults with

Subcutaneous Alemtuzumab in Fludarabine-
Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
✍ Stilgenbauer, S.; Zenz, T.; Winkler, D.; Buhler, A.; Schlenk, R. F.; Groner, S.; πŸ“‚ Article πŸ“… 2009 πŸ› American Society of Clinical Oncology 🌐 English βš– 170 KB

## Purpose The phase II CLL2H trial evaluated safety and efficacy of subcutaneous alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). Clinical and biologic markers were evaluated for their impacts on outcome. ## Patients and Methods One hundred nine patients